ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "mycophenolate mofetil and systemic sclerosis"

  • Abstract Number: 3175 • ACR/ARHP Annual Meeting 2016

    Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation

    Diana Toledo1, Monique Hinchcliff2, Jaclyn Taroni1, Tammara A. Wood3, Jennifer Franks3, Sanjiv Shah4, Rishi Agrawal4, Lauren Beussink-Nelson4, Mary A. Carns5, Sofia Podlusky6, Patricia Pioli7 and Michael Whitfield3, 1Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 3Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 4Northwestern University, Chicago, IL, 5Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, 6Rheumatology Feinberg School of Medicine, Northwestern University, Chicago, IL, 7Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: We previously showed patients in the inflammatory subset were most likely to demonstrate improvement in modified Rodnan Skin Score (mRSS) during mycophenolate mofetil (MMF)…
  • Abstract Number: 1076 • ACR/ARHP Annual Meeting 2015

    Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

    Elizabeth R. Volkmann1, Michael Roth2, Robert Elashoff3, Philip J. Clements1, Daniel E. Furst2, Dinesh Khanna4, Jonathan Goldin5, Donald Tashkin1 and Scleroderma Lung Study II Group, 1Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA, 4Medicine, University of Michigan, Ann Arbor, MI, 5David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
  • Abstract Number: 2962 • ACR/ARHP Annual Meeting 2015

    Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis

    Javier Narváez1, Helena Borrell Paños2, Ivan Castellvi3, Sergi Heredia2, Milena Millan3, Susana Herrera4, Eulalia Armengol2, Josep María LLobet3, Joan Miquel Nolla2, María Molina5 and Juan José Alegre6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 5Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain

    Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology